Back to News
Market Impact: 0.2
Investor Determination to Beat Cancer Puts NeOnc’s Novel Therapies and Patented Platform in Focus
Source: GlobeNewswire
Insider TransactionsHealthcare & BiotechPrivate Markets & Venture
NeOnc CEO purchased an additional 37,000 shares of NTHI common stock following a $15 financing involving healthcare-focused institutions. The insider buying signals management confidence, while the financing adds capital support; the disclosed financing amount lacks a stated unit.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
NTHI0.45
More News
- OpenAI raises just $11bn of $30bn target as AI investor appetite cools
- Anthropic's IPO push includes a big bet on life sciences
- Waymo’s backers valued it at $126 billion. The Alphabet division that houses it brought in $372 million last quarter—and lost $2.05 billion
- UnitedHealth is finally getting its act together. I'm buying into the turnaround
- Nvidia weighs playing the cosigner for Nscale’s AI data center in West Virginia
- Illumina CEO on Q3 Results and Business Outlook